- Home
- NWSA vs RPRX Comparison
NWSA vs RPRX Comparison
Compare NWSA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWSA
- RPRX
- Stock Information
- Founded
- NWSA 2012
- RPRX 1996
- Country
- NWSA United States
- RPRX United States
- Employees
- NWSA N/A
- RPRX N/A
- Industry
- NWSA Newspapers/Magazines
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- NWSA Consumer Discretionary
- RPRX Health Care
- Exchange
- NWSA Nasdaq
- RPRX Nasdaq
- Market Cap
- NWSA 16.3B
- RPRX 14.2B
- IPO Year
- NWSA N/A
- RPRX 2020
- Fundamental
- Price
- NWSA $28.48
- RPRX $33.10
- Analyst Decision
- NWSA Strong Buy
- RPRX Strong Buy
- Analyst Count
- NWSA 6
- RPRX 4
- Target Price
- NWSA $38.80
- RPRX $42.50
- AVG Volume (30 Days)
- NWSA 2.9M
- RPRX 3.9M
- Earning Date
- NWSA 05-08-2025
- RPRX 05-08-2025
- Dividend Yield
- NWSA 0.70%
- RPRX 2.66%
- EPS Growth
- NWSA 82.04
- RPRX 37.42
- EPS
- NWSA 0.72
- RPRX 2.45
- Revenue
- NWSA $10,253,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- NWSA N/A
- RPRX $31.30
- Revenue Next Year
- NWSA $0.62
- RPRX $5.82
- P/E Ratio
- NWSA $37.63
- RPRX $13.52
- Revenue Growth
- NWSA 13.34
- RPRX 1.12
- 52 Week Low
- NWSA $22.65
- RPRX $24.05
- 52 Week High
- NWSA $30.69
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- NWSA 66.20
- RPRX 57.01
- Support Level
- NWSA $27.07
- RPRX $31.97
- Resistance Level
- NWSA $27.22
- RPRX $33.00
- Average True Range (ATR)
- NWSA 0.64
- RPRX 0.71
- MACD
- NWSA 0.24
- RPRX 0.08
- Stochastic Oscillator
- NWSA 90.91
- RPRX 60.08
About NWSA News Corporation
News Corporation is a diversified media conglomerate with significant presence in the us, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. The company also has a strong presence in the Australian subscription video market through 65%-owned Foxtel, and streaming platforms such as sport-focused Kayo and entertainment-focused Binge. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the biggest book publishers in the world, and has a sizable us digital property advertising business, Move.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.